AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InspireMD Launches CGuard Prime Stent System, Potentially Reducing Embolism Risk, with Analysts Predicting an Upside of 99.12%
ByAinvest
Thursday, Jul 10, 2025 4:52 am ET1min read
InspireMD has launched its CGuard Prime carotid stent system in the US, following FDA approval. The device features a dual-layer structure, MicroNet mesh, and SmartFit technology to reduce the risk of early and late embolism. Based on analyst forecasts, the average target price is $4.50, implying a 99.12% upside from the current price. The company is optimistic about receiving FDA approval for its Seaguard Prime stent in Q3 2025, expected to drive significant demand.
Title: InspireMD Launches CGuard Prime Carotid Stent System in the USInspireMD (NASDAQ:NSPR) has successfully launched its CGuard Prime carotid stent system in the United States following FDA premarket approval. The device, designed to significantly reduce the risk of early and late embolism, features a dual-layer structure, MicroNet mesh, and SmartFit technology.
The CGuard Prime combines an open-cell frame with the smallest mesh pore size available, effectively trapping potential emboli against arterial walls while maintaining external carotid artery perfusion. The system also incorporates MicroNet technology, a bio-stable mesh made from a single 20-micrometer Polyethylene Terephthalate strand, and SmartFit technology, which eliminates the need for tapered versions.
InspireMD's CEO, Marvin Slosman, stated, "Our U.S. commercial launch marks a pivotal milestone in InspireMD’s expansion history, having already secured double-digit market share across more than 30 countries." The company is preparing for the launch with a robust commercial team and operational infrastructure.
Based on analyst forecasts, the average target price for InspireMD Inc (NSPR) is $4.50, implying a 99.12% upside from the current price. The company is optimistic about receiving FDA approval for its Seaguard Prime stent in Q3 2025, which is expected to drive significant demand.
References
1. [https://www.massdevice.com/inspiremd-launches-carotid-stent-us/](https://www.massdevice.com/inspiremd-launches-carotid-stent-us/)
2. [https://ca.investing.com/news/company-news/inspiremd-launches-cguard-prime-carotid-stent-in-us-after-fda-approval-93CH-4094763](https://ca.investing.com/news/company-news/inspiremd-launches-cguard-prime-carotid-stent-in-us-after-fda-approval-93CH-4094763)
3. [https://www.gurufocus.com/news/2966038/inspiremd-nspr-launches-cguard-prime-carotid-stent-system-in-the-us-nspr-stock-news](https://www.gurufocus.com/news/2966038/inspiremd-nspr-launches-cguard-prime-carotid-stent-system-in-the-us-nspr-stock-news)
4. [https://www.investing.com/news/stock-market-news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-93CH-4128239](https://www.investing.com/news/stock-market-news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-93CH-4128239)
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet